Abstract
Severe infections are common in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We aimed to describe the characteristics of patients with AAV and severe infections according to clinical phenotype. Retrospective cohort study including patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Baseline characteristics were compared between patients with and without at least one severe infection. Demographics, comorbidities, clinical characteristics, laboratory and treatment were retrieved at diagnosis and at every infectious event. One hundred and eight patients were included (57 with and 51 without infections). Patients with an infection had received more frequently methylprednisolone boluses at AAV diagnosis than patients without infections (OR 2.6, 95% CI 1.1–5.9, p = 0.01). There were a total of 108 severe infections in 57 patients (median follow-up 18 months). Thirty-two patients (56%) had an infectious complication within the first year of AAV diagnosis, 43 (75%) had pulmonary involvement during the first infection. The most frequent type of infection was pneumonia. Phenotypes were: Non-severe AAV (n = 11), severe PR3-AAV (n = 30), severe MPO-AAV (n = 9); the number of infectious events in each group was 11, 69, 18, respectively. Patients with severe MPO phenotype were older and required more frequently ICU stay compared to other phenotypes. Positive correlation was found between total of infections and pulmonary infiltrates due to vasculitis (ρ = 0.40, p = 0.003), endobronchial involvement (ρ = 0.40, p = 0.003), and alveolar hemorrhage (ρ = 0.34, p = 0.015). Severe infections, most commonly pneumonia, were frequent in this cohort, especially during the first year after diagnosis, in patients with pulmonary involvement and severe PR3 phenotype who received methylprednisolone boluses.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00296-020-04661-x/MediaObjects/296_2020_4661_Fig1_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00296-020-04661-x/MediaObjects/296_2020_4661_Fig2_HTML.png)
Similar content being viewed by others
References
Cornec D, Cornec-Le Gall E, Fervenza FC, Specks U (2016) ANCA-associated vasculitis-clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol 12:570–579
Tadema H, Heeringa P, Kallenberg CG (2011) Bacterial infections in Wegener's granulomatosis: mechanisms potentially involved in autoimmune pathogenesis. Curr Opin Rheumatol 23:366–371
McGregor JG, Negrete-Lopez R, Poulton CJ et al (2015) Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function. Nephrol Dial Transplant 30(Suppl 1):i171–i181
Yoo J, Jung SM, Song JJ, Park YP, Lee SW (2018) Birmingham vasculitis activity and chest manifestation at diagnosis can predict hospitalised infection in ANCA-associated vasculitis. Clin Rheumatol 37:2133–2141
Wall N, Harper L (2012) Complications of long-term therapy for ANCA-associated systemic vasculitis. Nat Rev Nephrol 8:523–532
Flossmann O, Berden A, de Groot K et al (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70:488–494
Lionaki S, Blyth ER, Hogan SL et al (2012) Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 64:3452–3462
Watts RA, Mahr A, Mohammad AJ, Gatenby P, Basu N, Flores-Suárez LF (2015) Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant 30(Suppl 1):i14–22
Mahr A, Specks U, Jayne D (2019) Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum. Rheumatology (Oxford) 58:1707–1709
Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1–11
Leavitt RY, Fauci AS, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 33:1101–1107
Stone JH, Hoffman GS, Merkel PA et al (2001) A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 44:912–920
Hellmich B, Flossmann O, Gross WL et al (2007) EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-asssociated vasculitis. Ann Rheum Dis 66:605–617
Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228
Lao M, Huang M, Li C et al (2020) Infectious profile in inpatients with ANCA-associated vasculitis: a single-center retrospective study from Southern China. Clin Rheumatol 39:499–507
Little MA, Nightingale P, Verburgh CA et al (2010) Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 69:1036–1043
Kronbichler A, Jayne DR, Mayer G (2015) Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest 45:346–368
Watanabe-Imai K, Harigai M, Sada KE et al (2017) Clinical characteristics of and risk factors for serious infection in Japanese patients within six months of remission induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis registered in a nationwide, prospective, inception cohort study. Mod Rheumatol 27:646–651
Harper L, Savage CO (2005) ANCA-associated renal vasculitis at the end of the twentieth century-a disease of older patients. Rheumatology (Oxford) 44:495–501
Lafarge A, Joseph A, Pagnoux C et al (2019) Predictive factors of severe infections in patients with systemic necrotizing vasculitides: data from 733 patients enrolled in five randomized controlled trials of the French Vasculitis Stugy Group. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/kez575
Charlier C, Henegar C, Launay O et al (2009) Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis 68:658–663
Waki D, Nishimura K, Tokumasu H et al (2020) Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective observational study. Medicine (Baltimore) 99(8):e19173. https://doi.org/10.1097/MD.0000000000019173
Chanouzas D, McGregor JA, Nightingale P et al (2019) Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated vascultis: a multi-center retrospective cohodrt study. BMC Nephrol 20(1):58
Walsh M, Merkel PA, Peh CA et al (2020) Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Eng J Med 382:622–631
Kallenberg CG, Tadema H (2008) Vascultitis and infections: contribution to the issue of autoimmunity reviews devoted to “autoimmunity and infection”. Autoimmun Rev 8:29–32
Lai QY, Ma TT, Li ZY, Chang DY, Zhao MH, Chen M (2014) Predictors for mortality in patients with antineutrophil cytoplasmic autoantibody-assocaited vasculitis: a study of 398 Chinese patients. J Rheumatol 41:1849–1855
Garcia-Vives E, Segarra-Medrano A, Martinez-Valle F, Agraz I, Solans-Laque R (2020) Prevalence and risk factors for major infections in patients with antineutrophil cytoplasmic antibody-associated vasculitis: influence on the disease outcome. J Rheumatol 47:407–414
Ono N, Inoue Y, Miyamura T et al (2019) The association of airway comorbidities with the clinical phenotypes and outcomes of ANCA-associated vasculitis patients. J Rheumatol. https://doi.org/10.3899/jrheum.190373
Konstantinov KN, Ulff-Møller CJ, Tzamaloukas AH (2015) Infections and antineutrophil cytoplasmic antibodies: triggering mechanisms. Autoimmun Rev 14:201–203
Funding
The authors declare that this work was not supported by any Grant or funding.
Author information
Authors and Affiliations
Contributions
AECI and AHA contributed to the conception and design of the work; AECI, IHU, AGC and AHA participated in the acquisition, analysis, and interpretation of data; AECI, IHU and AHA drafted the work and revised it critically for important intellectual content; AECI, IHU, AGC and AHA gave final approval of the version to be published and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Corresponding author
Ethics declarations
Conflict of interest
AECI, IHU, AGC and AHA declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Caballero-Islas, A.E., Hoyo-Ulloa, I., García-Castro, A. et al. Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a retrospective cohort study with a clinical phenotype approach. Rheumatol Int 40, 1657–1666 (2020). https://doi.org/10.1007/s00296-020-04661-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-020-04661-x